Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
Jeanne Tie, Peter Gibbs, Lara Lipton, Michael Christie, Robert N Jorissen, Antony W Burgess, Matthew Croxford, Ian Jones, Rachel Langland, Suzanne Kosmider, Daniel McKay, Gideon Bollag, Keith Nolop, Oliver M Sieber, Jayesh Desai
International Journal of Cancer | WILEY | Published : 2011
Awarded by NHMRC
Grant sponsor: Plexxikon Incorporated, Roche Molecular Systems, Victorian Government (Victorian Cancer Agency Clinical Researcher Fellowship); Grant sponsor: NHMRC Medical and Dental Postgraduate Research Scholarship; Grant number: 487925The authors acknowledge the technical contribution of Ms. Jessie Wang, Ms. Mara Giovanetti, Mr. Matthew Chapman, Ms. Cheryl Augustine, Ms. Julie Johns and Mr. Michael Harold to this study. Dr. J. Tie holds an NHMRC Medical and Dental Postgraduate Research Scholarship. Dr. L. Lipton is supported by the Victorian Government through a Victorian Cancer Agency Clinical Researcher Fellowship. This research was supported in part by the Operational Infrastructure Support Program funding provided by the Victorian Government, Australia.